The data is clear and consistent: most patients who stop GLP-1 therapy regain significant weight. Understanding the biology behind this — and the strategies to mitigate it — is essential for informed treatment decisions.
Weight regain after stopping GLP-1 medications is the most important topic in obesity medicine that patients aren't hearing about early enough. The evidence is now robust, consistent across multiple trials, and demands honest discussion before treatment begins — not after a patient decides to stop.
A BMJ meta-analysis published in January 2026 — analyzing 37 studies and 9,341 participants — quantified the regain rate with unprecedented precision. Patients who discontinued semaglutide or tirzepatide regained an average of 0.8 kg (about 1.8 lbs) per month. Over the first year off medication, average regain was 9.9 kg (nearly 22 lbs). At that trajectory, the researchers projected return to baseline weight within approximately 1.5 years of stopping treatment.
This aligns with the landmark trials. The STEP 1 extension trial showed that approximately two-thirds of weight lost with semaglutide was regained within one year of discontinuation. The SURMOUNT-4 trial — which randomized tirzepatide patients to continued treatment or placebo after 36 weeks — found that the placebo group regained more than half their lost weight over the subsequent 52 weeks, while those who continued tirzepatide kept losing.
Weight regain after medication discontinuation follows the same biological logic as regain after dieting — but potentially more abruptly, because the medication was suppressing appetite signals that return in full force when the drug clears your system.
Your body treats weight loss as a threat, regardless of whether you lost weight through diet, exercise, surgery, or medication. It responds by increasing hunger hormones (ghrelin), decreasing satiety hormones (leptin), and reducing resting metabolic rate. These adaptations persist for years — possibly permanently. GLP-1 medications override these signals while active. Remove the medication, and the signals return — often with a temporary overshoot (the "hunger rebound" many patients describe as feeling hungrier than before they ever started treatment).
The weight regain evidence has shifted how obesity medicine specialists think about GLP-1 therapy. The emerging consensus: obesity is a chronic disease that requires chronic treatment, similar to hypertension or type 2 diabetes. Nobody questions whether blood pressure patients should "eventually stop" their medication. The same logic increasingly applies to obesity treatment.
This doesn't mean everyone needs full-dose GLP-1 therapy indefinitely. Some patients and providers are exploring reduced maintenance doses — enough to keep appetite signals managed without the cost and side effect burden of the maximum weight-loss dose. Evidence on optimal maintenance dosing is still building, but clinical experience suggests that even lower doses can prevent the full regain seen with complete discontinuation.
Before starting: Understand that GLP-1 therapy may be a long-term commitment. Factor this into your financial planning and expectations.
During treatment: Use the appetite suppression window to build habits (protein-forward eating, resistance training, sleep optimization) that will partially mitigate regain if you do eventually stop. These habits won't prevent all regain, but they can slow it.
Considering stopping: Discuss tapering rather than abrupt cessation with your provider. Have a monitoring plan in place. And be realistic: some regain is biologically normal and doesn't mean you failed.
The affordability factor: With prices dropping (Wegovy tablets at $149/month, list prices falling to $675 in 2027, Medicare coverage starting July 2026), long-term maintenance is becoming more financially feasible. See our guide to affordable options.
For a detailed guide on discontinuation strategies, see our companion article: Stopping Weight Loss Medication: What Happens and How to Prepare.
$350 CPA — long-term programs
Treatment programs designed for sustained success, including maintenance phase planning and ongoing provider relationships.
Get Started →GLP-1 programs with flexibility
Options for both active weight loss and maintenance dosing, with provider guidance on long-term planning.
Learn More →$300 CPA — comprehensive weight loss
Programs that address the full treatment arc, including the critical maintenance and potential discontinuation phases.
Check Availability →